Further Mixed Results For GSK/Theravance’s Relovair Have Investors Holding Breath
This article was originally published in The Pink Sheet Daily
GSK and Theravance released preliminary results of two Phase III studies for their COPD drug Relovair that could serve to help differentiate the drug from Advair.
You may also be interested in...
GSK R&D President Patrick Vallance On Increasing R&D Productivity: An Interview With PharmAsia News (Part 2 of 2)
An R&D model aimed at bringing the pressure and promise of startups to life within GlaxoSmithKline PLC continues to be tweaked, according to Patrick Vallance, president of pharmaceuticals R&D. He sat down with PharmAsia News during a recent visit to Singapore to give an overview of the company’s strategy.
The respiratory drug’s fate is uncertain given its mixed Phase III trial results; in two pivotal studies Breo, formerly Relovair, failed to demonstrate superiority to GSK’s Advair.
Mixed Phase III data results on GSK/Theravance’s once-daily follow-up to Advair raises the regulatory and commercial stakes for the drug, a crucial pipeline product for both companies